BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 10075964)

  • 21. Efficacy and safety of ursodeoxycholic acid in primary, type IIa or IIb hypercholesterolemia: a multicenter, randomized, double-blind clinical trial.
    Braga MF; Grace MG; Lenis J; Kennedy FP; Teplinsky AL; Roederer G; Palumbo PJ; Colin P; Leiter LA
    Atherosclerosis; 2009 Apr; 203(2):479-82. PubMed ID: 18801487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
    Stiehl A; Rudolph G; Sauer P; Theilmann L
    J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bile acid patterns in meconium are influenced by cholestasis of pregnancy and not altered by ursodeoxycholic acid treatment.
    Rodrigues CM; Marín JJ; Brites D
    Gut; 1999 Sep; 45(3):446-52. PubMed ID: 10446117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia.
    Smit JW; Van Erpecum KJ; Portincasa P; Renooij W; Erkelens DW; Van Berge-Henegouwen GP
    Gut; 1995 Nov; 37(5):654-9. PubMed ID: 8549941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ursodeoxycholic acid decreases viscosity and sedimentable fractions of gallbladder bile in patients with cholesterol gallstones.
    Fischer S; Müller I; Zündt BZ; Jüngst C; Meyer G; Jüngst D
    Eur J Gastroenterol Hepatol; 2004 Mar; 16(3):305-11. PubMed ID: 15195895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.
    Dilger K; Hohenester S; Winkler-Budenhofer U; Bastiaansen BA; Schaap FG; Rust C; Beuers U
    J Hepatol; 2012 Jul; 57(1):133-40. PubMed ID: 22414767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate.
    Rudolph G; Kloeters-Plachky P; Sauer P; Stiehl A
    Eur J Clin Invest; 2002 Aug; 32(8):575-80. PubMed ID: 12190957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.
    Leuschner M; Maier KP; Schlichting J; Strahl S; Herrmann G; Dahm HH; Ackermann H; Happ J; Leuschner U
    Gastroenterology; 1999 Oct; 117(4):918-25. PubMed ID: 10500075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis].
    Avezov SA; Mansurov FKh
    Klin Med (Mosk); 2004; 82(3):55-8. PubMed ID: 15114777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice.
    Cai SY; Mennone A; Soroka CJ; Boyer JL
    J Pharmacol Exp Ther; 2014 Apr; 349(1):94-8. PubMed ID: 24492652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LDL cholesterol lowering by bile acid malabsorption during inhibited synthesis and absorption of cholesterol in hypercholesterolemic coronary subjects.
    Gylling H; Miettinen TA
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):19-23. PubMed ID: 12125225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
    Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
    Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of combined use of ursodeoxycholic acid and heptral in the treatment of primary biliary cirrhosis].
    Avezov SA; Mansurova FKh
    Klin Med (Mosk); 2004; 82(2):46-9. PubMed ID: 15106512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in bile acid composition and effect on cytolytic activity of fecal water by ursodeoxycholic acid administration: a placebo-controlled cross-over intervention trial in healthy volunteers.
    van Gorkom BA; van der Meer R; Boersma-van Ek W; Termont DS; de Vries EG; Kleibeuker JH
    Scand J Gastroenterol; 2002 Aug; 37(8):965-71. PubMed ID: 12229974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis.
    Combes B; Emerson SS; Flye NL; Munoz SJ; Luketic VA; Mayo MJ; McCashland TM; Zetterman RK; Peters MG; Di Bisceglie AM; Benner KG; Kowdley KV; Carithers RL; Rosoff L; Garcia-Tsao G; Boyer JL; Boyer TD; Martinez EJ; Bass NM; Lake JR; Barnes DS; Bonacini M; Lindsay KL; Mills AS; Markin RS; Rubin R; West AB; Wheeler DE; Contos MJ; Hofmann AF
    Hepatology; 2005 Nov; 42(5):1184-93. PubMed ID: 16250039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of administration of ursodeoxycholic acid at bedtime on cholesterol saturation of hepatic bile in Japanese patients with gallstone.
    Inoi J; Shimizu I; Tsuji Y; Muguruma N; Shibata H; Ito S
    J Med Invest; 1998 Aug; 45(1-4):115-22. PubMed ID: 9864972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid.
    Combes B; Carithers RL; Maddrey WC; Munoz S; Garcia-Tsao G; Bonner GF; Boyer JL; Luketic VA; Shiffman ML; Peters MG; White H; Zetterman RK; Risser R; Rossi SS; Hofmann AF
    Hepatology; 1999 Jun; 29(6):1649-54. PubMed ID: 10347103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases.
    Festi D; Montagnani M; Azzaroli F; Lodato F; Mazzella G; Roda A; Di Biase AR; Roda E; Simoni P; Colecchia A
    Curr Clin Pharmacol; 2007 May; 2(2):155-77. PubMed ID: 18690863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
    Robinson JG; Ballantyne CM; Grundy SM; Hsueh WA; Parving HH; Rosen JB; Adewale AJ; Polis AB; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2009 Jun; 103(12):1694-702. PubMed ID: 19539078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of ursodeoxycholic acid in patients with liver disease.
    Angulo P
    Curr Gastroenterol Rep; 2002 Feb; 4(1):37-44. PubMed ID: 11825540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.